G1 Therapeutics Inc (NASDAQ:GTHX) insider Rajesh Malik sold 3,776 shares of G1 Therapeutics stock in a transaction on Monday, September 17th. The stock was sold at an average price of $66.08, for a total value of $249,518.08. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
GTHX stock traded down $0.02 during trading on Friday, hitting $42.98. The stock had a trading volume of 279,513 shares, compared to its average volume of 278,142. G1 Therapeutics Inc has a 1-year low of $18.03 and a 1-year high of $69.57. The company has a market capitalization of $1.75 billion, a price-to-earnings ratio of -12.04 and a beta of -1.02.
G1 Therapeutics (NASDAQ:GTHX) last announced its earnings results on Wednesday, August 8th. The company reported ($0.64) earnings per share for the quarter, beating the consensus estimate of ($0.65) by $0.01. On average, sell-side analysts predict that G1 Therapeutics Inc will post -2.68 EPS for the current year.
GTHX has been the subject of several research reports. BidaskClub raised G1 Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, June 16th. Zacks Investment Research downgraded G1 Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, July 11th. Cowen reaffirmed a “buy” rating on shares of G1 Therapeutics in a research note on Thursday, August 9th. JPMorgan Chase & Co. lifted their price target on G1 Therapeutics from $58.00 to $63.00 and gave the stock an “overweight” rating in a research note on Friday, August 10th. Finally, BTIG Research initiated coverage on G1 Therapeutics in a research note on Monday, September 10th. They set a “buy” rating and a $80.00 price target for the company. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $74.50.
About G1 Therapeutics
G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer in the United States. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase 1b/2a clinical trials for patients with small cell lung cancer, as well as Phase 2 clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; G1T38, an oral CDK4/6 inhibitor that is Phase 1b/2a clinical trials for the treatment of breast cancer; and G1T48, an oral selective estrogen receptor degrader, which is in preclinical development.
Recommended Story: Determine Your Level of Risk Tolerance
Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.